Effectiveness of 730 nm Picosecond Laser for the Treatment of Freckles and Solar Lentigines: A Retrospective Analysis

IF 3.7 4区医学 Q1 DERMATOLOGY

Dermatologic Therapy Pub Date : 2023-11-23 DOI:10.1155/2023/2070560

Qilei Che, Qingbiao Wa, Lufeng Liu, Qiuyue Tang, Yulian Gao, Jie Lu, Zixuan Zhou, Yuhong Xie

{"title":"Effectiveness of 730 nm Picosecond Laser for the Treatment of Freckles and Solar Lentigines: A Retrospective Analysis","authors":"Qilei Che, Qingbiao Wa, Lufeng Liu, Qiuyue Tang, Yulian Gao, Jie Lu, Zixuan Zhou, Yuhong Xie","doi":"10.1155/2023/2070560","DOIUrl":null,"url":null,"abstract":"Background. Freckles and solar lentigines are epidermal pigmentation disorders that affect the face and impact the quality of life of affected individuals. Aims. We aimed to observe and evaluate the clinical effectiveness of a 730 nm picosecond laser for the treatment of freckles and solar lentigines. Methods. We retrospectively collected patient information on freckles and solar lentigines and observed and evaluated the clinical outcome of a 730 nm picosecond laser. These included lesion clearance and recurrence rates, adverse reactions, and patient satisfaction. Results. Fifty cases of freckles and solar lentigines reported between January 1, 2022, and July 1, 2022, were included. All patients received two 730 nm picosecond laser treatments. The lesion clearance rates after one and two treatments were 53.1% and 78.4%, respectively, and the rates after one and six months of treatment were 78.7% and 78.4%, respectively. 90% of the patients reported ≥95% clearance of lesions after six months via a questionnaire survey. Among the patients, 86.0% were satisfied with their treatment. Postinflammatory hyperpigmentation occurred in two patients, both of whom had Fitzpatrick skin type IV. There was no recurrence of lesions. Conclusions. The 730 nm picosecond laser treatment for freckles and solar lentigines has the advantages of a high clearance rate, low recurrence rate, and high patient satisfaction. This trial is registered with ChiCTR2200058573.","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"48 18 1","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2023-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatologic Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2023/2070560","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background. Freckles and solar lentigines are epidermal pigmentation disorders that affect the face and impact the quality of life of affected individuals. Aims. We aimed to observe and evaluate the clinical effectiveness of a 730 nm picosecond laser for the treatment of freckles and solar lentigines. Methods. We retrospectively collected patient information on freckles and solar lentigines and observed and evaluated the clinical outcome of a 730 nm picosecond laser. These included lesion clearance and recurrence rates, adverse reactions, and patient satisfaction. Results. Fifty cases of freckles and solar lentigines reported between January 1, 2022, and July 1, 2022, were included. All patients received two 730 nm picosecond laser treatments. The lesion clearance rates after one and two treatments were 53.1% and 78.4%, respectively, and the rates after one and six months of treatment were 78.7% and 78.4%, respectively. 90% of the patients reported ≥95% clearance of lesions after six months via a questionnaire survey. Among the patients, 86.0% were satisfied with their treatment. Postinflammatory hyperpigmentation occurred in two patients, both of whom had Fitzpatrick skin type IV. There was no recurrence of lesions. Conclusions. The 730 nm picosecond laser treatment for freckles and solar lentigines has the advantages of a high clearance rate, low recurrence rate, and high patient satisfaction. This trial is registered with ChiCTR2200058573.

查看原文本刊更多论文

730 nm 皮秒激光治疗雀斑和日光性色斑的效果：回顾性分析

背景。雀斑和日光性色斑是表皮色素沉着疾病，会影响面部，影响患者的生活质量。目的我们旨在观察和评估 730 nm 皮秒激光治疗雀斑和日光性色斑的临床效果。方法我们回顾性地收集了雀斑和日光痣患者的信息，并观察和评估了 730 nm 皮秒激光的临床效果。其中包括皮损清除率和复发率、不良反应和患者满意度。结果共纳入 2022 年 1 月 1 日至 2022 年 7 月 1 日期间报告的 50 例雀斑和日光性色素痣病例。所有患者均接受了两次 730 纳米皮秒激光治疗。经过一次和两次治疗后，皮损清除率分别为53.1%和78.4%，治疗一个月和六个月后的清除率分别为78.7%和78.4%。通过问卷调查，90%的患者表示六个月后病灶清除率≥95%。86.0%的患者对治疗表示满意。有两名患者出现了炎症后色素沉着，这两名患者都属于菲茨帕特里克皮肤 IV 型。皮损没有复发。结论730 nm 皮秒激光治疗雀斑和日光性色斑具有清除率高、复发率低和患者满意度高的优点。本试验的注册号为 ChiCTR2200058573。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Dermatologic Therapy 医学-皮肤病学

CiteScore

7.00

自引率

8.30%

发文量

711

审稿时长

3 months

期刊介绍： Dermatologic Therapy has been created to fill an important void in the dermatologic literature: the lack of a readily available source of up-to-date information on the treatment of specific cutaneous diseases and the practical application of specific treatment modalities. Each issue of the journal consists of a series of scholarly review articles written by leaders in dermatology in which they describe, in very specific terms, how they treat particular cutaneous diseases and how they use specific therapeutic agents. The information contained in each issue is so practical and detailed that the reader should be able to directly apply various treatment approaches to daily clinical situations. Because of the specific and practical nature of this publication, Dermatologic Therapy not only serves as a readily available resource for the day-to-day treatment of patients, but also as an evolving therapeutic textbook for the treatment of dermatologic diseases.